Cannabinoids and the Aging Brain: Why Dose and Product Type Matter
A 2026 review highlights how cannabinoid therapy aging brain effects depend on dose, product type, and aging physiology. The findings emphasize careful, age-adapted decisions over broad claims. This supports safer cannabis use tailored to older adults'…
Cannabinoids and Inflammation: A Systematic Review of Clinical Evidence
Cannabinoid use inflammatory biomarkers show complex associations with both pro- and anti-inflammatory markers. Clinical evidence reveals nuanced immunomodulatory effects rather than a simple inflammatory shift. Understanding these biomarkers is critical…
Exploring the Endocannabinoid System in Opioid Use Disorder and Pain
A 2026 review explores the endocannabinoid system opioid use disorder connection and its potential role in managing pain and withdrawal symptoms. The biology is plausible but clinical translation remains limited by small studies and mixed designs. This…
Cannabis and Cognition in Adolescents and Young Adults: A New Systematic Review
A 2026 systematic review highlights adolescent cannabis memory effects as the most consistent cognitive difference in young users. Memory-related findings, especially episodic and working memory, stand out more than other cognitive domains. This review…
Cannabinoids for Cancer Pain: New Review Questions the Opioid-Sparing Claim
A 2026 systematic review and meta-analysis found cannabinoids did not reliably reduce opioid use in controlled cancer-pain studies. This challenges the opioid-sparing cancer pain claim often made in clinical discussions. The findings suggest cannabinoids…
Cannabis Use and Poor Mental Health: What the New U.S. Trends Show
The 2023 cannabis mental health data reveals an increase in poor mental health days among adults reporting cannabis use. This large U.S. survey highlights the need for better mental health screening. However, it does not prove cannabis caused the trend.
High-Dose CBD for Spinal Cord Injury Nerve Pain
The high-dose cannabidiol neuropathic pain trial showed modest reduction in spinal cord injury nerve pain. This randomized crossover study tested doses up to 800 mg daily. Results indicate a credible analgesic signal but do not support unsupervised…
Autism, Schizophrenia, and Shared Biology: Why This Review Is Not Really a Cannabis Paper
This review explores shared biology autism schizophrenia, emphasizing overlapping molecular and cellular pathways. It highlights endocannabinoid dysfunction as one component among many. The paper is conceptual and not a cannabis treatment guide.
Bernie Sanders Once Again Asking
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
A Cannabis-Based Medicine Goes Head-to-Head With Lorazepam for Sleep
A cannabis insomnia randomized trial published in 2026 compared a traditional cannabis-based herbal medicine with lorazepam for chronic insomnia. Both groups experienced substantial improvements in sleep quality, quality of life, and stress scores over…
